Medios Aims for €3.1 Billion Revenue by 2031

Medios AG announces its “Medios Next Level” strategy, targeting €3.1 billion in revenue by 2031, with adjusted EBITDA expected to double to €170 million. The strategy involves a shift from Specialty Pharma to Pharma Services, focusing on two segments: Specialty Pharma Supply and Compounding.

The company plans for profitable growth, aiming for a 5% organic revenue CAGR, while maintaining a net debt/EBITDA ceiling of 2.0x. The strategy includes international expansion, selective M&A, and operational excellence.

The strategy is based on a decade of success, with Medios transitioning to a technology-driven Pharma Services Group. The planned acquisition of Caesar & Loretz strengthens its Compounding segment. Medios aims to capitalize on growth opportunities in Specialty Pharma and Compounding markets, driven by the demand for individualized therapies.